Drug does not significantly reduce risk of death among patients with severe sepsis

March 19, 2013

Administration of the drug eritoran to patients with severe sepsis and septic shock failed to demonstrate a significant effect on reducing all-cause 28-day mortality or 1-year mortality, compared with placebo, according to a study in the March 20 issue of JAMA.

Severe sepsis, a syndrome of complicated by , is caused by a dysregulated systemic inflammatory response. Sepsis can progress to systemic hypotension (), multiple organ dysfunction, and death. "Lipopolysaccharide (LPS) or endotoxin, the major component of the of gram-negative bacteria, is a potent stimulator of the inflammatory response. LPS triggers inflammation in gram-negative sepsis," according to background information in the article. Eritoran, a synthetic analog (a substance that is similar, but not identical, to another) of A, is a potent and specific antagonist of LPS action. In a phase 2 trial, eritoran-treated patients at of death had lower mortality that was not statistically significant.

Steven M. Opal, M.D., of the Alpert Medical School of Brown University, Providence, R.I., and colleagues conducted a trial to evaluate the safety and efficacy of eritoran in reducing mortality in patients with severe sepsis. The randomized, multinational trial was conducted in 197 intensive care units. Patients were enrolled from June 2006 to September 2010 and final follow-up was completed in September 2011. Patients with severe sepsis (n=1,961) were randomized and treated within 12 hours of onset of first organ dysfunction in a 2:1 ratio with a 6-day course of either eritoran tetrasodium (105 mg total) or placebo, with n=1,304 and n=657 patients, respectively. The primary end point for the study was 28-day all-cause mortality. The secondary end points were all-cause mortality at 3, 6, and 12 months after beginning treatment.

The researchers found that treatment with eritoran did not result in significant reductions in the primary study end point of 28-day mortality in the modified intent-to-treat analysis (randomized patients who received at least 1 dose) population; 28.1 percent (366/1,304) of patients in the eritoran group vs. 26.9 percent (177/657) of patients in the placebo group.

There was also no significant difference in the secondary end point of 1-year all-cause mortality: 44.1 percent (290/657) in the eritoran group vs. 43.3 percent (565/1,304) in the placebo group.

Eritoran was well tolerated with comparable numbers of treatment-emergent adverse events (TEAEs) and serious TEAEs between eritoran and placebo groups.

"These findings are in contrast with several preclinical studies and in phase 1 clinical trials in which eritoran terminated lipopolysaccharide-associated molecular and clinical events when administered in adequate doses. Despite these promising early results, no evidence of significant benefit was observed with eritoran in this large phase 3 trial," the authors write. "Eritoran joins a long list of other experimental sepsis treatments that do not improve outcomes in clinical trials in these critically ill patients."

Explore further: Combination antibiotic treatment does not result in less organ failure in adults with severe sepsis

More information: JAMA. 2013;309(11):1154-1162

Related Stories

Recommended for you

Resveratrol may be an effective intervention for lung aging

February 22, 2017

In a study led by Barbara Driscoll, PhD, of The Saban Research Institute of Children's Hospital Los Angeles, researchers demonstrate, for the first time that inhaled resveratrol treatments slow aging-related degenerative ...

Salmonella food poisoning could damage your DNA

February 22, 2017

Salmonella food poisoning wallops you for several days, but new research by Cornell food scientists indicates that some of its serotypes – variations of the bacterial species – can have permanent repercussions. It may ...

Risk of Ross River virus global epidemic

February 22, 2017

Australia's Ross River virus (RRV) could be the next mosquito-borne global epidemic according to a new research study led by the University of Adelaide and The Australian National University.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.